3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Sarcoma
1
Myelodysplastic Syndromes
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Acute
1
Hematologic Neoplasms
1
Interventions
fludarabine
52
Cyclophosphamide
50
venetoclax
47
Azacitidine
44
fludarabine phosphate
41
Whole-Body Irradiation
33
Specimen Handling
31
Mycophenolic Acid
30
Tacrolimus
28
Melphalan
28
Busulfan
27
Cytarabine
25
Stem Cell Transplantation
23
Decitabine
23
Biopsy
22
Granulocyte Colony-Stimulating Factor
19
Sirolimus
16
Peripheral Blood Stem Cell Transplantation
16
Filgrastim
16
Thiotepa
15
decitabine and cedazuridine drug combination
14
Injections
13
Cyclosporine
13
ruxolitinib
9
Methotrexate
9
Mesna
9
Hematopoietic Stem Cell Transplantation
9
X-Rays
8
Idarubicin
8
Daunorubicin
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Myelodysplastic Syndromes
×
bexmarilimab
×
1 year
×
Clear all
NCT05428969
2026-04-23
BEXMAB
Faron Pharmaceuticals Ltd
Phase 1/2
Active not recruiting
181 enrolled